Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

SSRI Antidepressants Not Tied to Cardiovascular Conditions

By Drug Discovery Trends Editor | March 23, 2016

Commonly prescribed antidepressants, called selective serotonin reuptake inhibitors (SSRIs) are not associated with an increased risk of heart conditions, such as heart attacks and stroke, according to recent research published in the BMJ.

While depression is known to increase the risk of cardiovascular problems, it has not been clear whether that risk is tied to antidepressant use. Previously, it’s been thought that SSRIs may affect coagulation, leading to cardiovascular disease — but this association has not been confirmed.

The Food and Drug Administration and the European Medicines Association both issued warnings in 2011 about the risk of taking high doses of citalopram (Celexa), one of the most commonly prescribed antidepressants. A dose of citalopram should not exceed 40 mg per day, both agencies said.

Yet, according to the BMJ study, citalopram, the most commonly prescribed antidepressant among patients in the study, was not associated with an increased risk of arrhythmia, even at higher doses. Still, the authors note that higher doses may pose a risk, because only 18 percent of the citalopram prescriptions in the study were for higher doses.

Researchers at The University of Nottingham analyzed a cohort of nearly 239,000 patients, ages 20 to 64, who had been diagnosed with depression. The patients were monitored for heart attacks, stroke, or transient ischaemic attacks and arrhythmia. When the researchers looked at tricyclic antidepressants, SSRIs and other types of antidepressants — and adjusted for age, gender, alcohol and tobacco use, other conditions and use of other medications — they didn’t see an increase in cardiovascular conditions among patients on SSRIs.

In a 5-year period, 772 patients had a myocardial infraction; 1,106 had a stroke of transient ischemic attack; and 1,452 had arrhythmia. But there was no evidence that SSRIs increased the risk of these cardiovascular conditions.

But during the first four weeks of taking tricyclic and related antidepressants, there was double the risk of experiencing arrhythmia.

“In addition, we found some indication that SSRIs were associated with a reduced risk of heart attacks, particularly with the use of fluoxetine (Prozac),” said study author Carol Coupland, of Nottingham University.

It’s important to note that these results do not prove a causative link, because this is an observational study.

Antidepressant use in the U.S. has skyrocketed: Adults in the U.S. consumed four times more antidepressants in the late 2000s than they did in the early 1990s. Antidepressants are the third most frequently taken drug in the U.S. and researchers estimate that 8 to 10 percent of the population is taking an antidepressant, according to the Centers for Disease Control and Prevention.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE